newsfilter
← Latest News
ACCESS Newswire·

AI Financial Corporation Rebrands Its Biotech Business as Drew Therapeutics in Honor of Andrew Witkoff, Who Succumbed to Opioid Addiction in 2011

AIFC
  • AI Financial Corporation (NASDAQ: AIFC) rebranded its biotech segment from Alyea Therapeutics to Drew Therapeutics Corporation to honor Andrew Witkoff, brother of Chairman Zach Witkoff, who died of an opioid overdose in 2011.
  • The new entity will operate as a separate, independent public company with the tagline "Out of Pain Comes Purpose" or "From Pain Comes Purpose."
  • Drew Therapeutics is led by Dr. Amol Soin, inventor of the Biphasic release of Low-Dose Naltrexone (LDN) & the "Clear Patch" topical technology for non-addictive pain relief.
  • The company's lead program involves a proprietary LDN formulation for Complex Regional Pain Syndrome (CRPS) that holds FDA orphan drug designation.
  • CEO Tony Isaac stated the rebranding reinforces the commitment to developing non-addictive pain treatments to address the opioid crisis, which has claimed over 700,000 American lives in the last decade.
  • Chairman Zach Witkoff emphasized the non-partisan nature of the opioid crisis, noting Americans consume 80% of the world's oxycodone despite comprising only 5% of the global population.
  • AI Financial is a fintech firm specializing in agentic commerce, while Drew Therapeutics focuses on non-opioid solutions for chronic pain.
  • CEO Isaac indicated that further strategic announcements & initiatives will be released in the coming weeks.